⭐ Welcome to our new Co-Director Professor Ben Colagiuri ⭐
We sat down to talk to Ben about his new role and what he's looking forward to at Brain and Mind Centre
Read our 'In Conversation with Ben' here -> bit.ly/InConversati...
Woman's headshot while she wears a blazer in front of a blurred castle
Start your year by revisiting one of our older episodes 🎙️
Dr. Muireann Irish shares how dementia changes memory, imagination, and joy.
Listen here: open.spotify.com/episode/0iuX...
Have you or someone you know been diagnosed with young onset dementia (onset < age 65)?
We’re conducting a research study on Australian's experiences accessing care and support (e.g. the NDIS) after diagnosis.
Learn more or take part: redcap.sydney.edu.au/surveys/?s=Y...
@fionakumfor.bsky.social
@ppaphasiaawareness.bsky.social
@brainandmindcentre.bsky.social
@utas.edu.au
@sydney.edu.au
Primary Progressive Aphasia Awareness Day Australia 2026
Free webinar: Friday 10 April, 12:00–1:30pm AEST (Zoom)
Hear from specialist clinicians on how early intervention supports people with PPA, including younger‑onset, to keep living well and doing what matters.
Register: bit.ly/PPAAwareness...
YOD‑SIG is hosting its first 2026 webinar on 12 March, 12:30–1:30pm AEDT.
Let us Grow explores how creative and inclusive activities can support people with young onset dementia to live meaningful, connected lives.
Register: events.humanitix.com/let-us-grow-...
#YOD #dementia
We’re pleased to share the personal story of Siân Jarrett. Her generous philanthropy has been instrumental in supporting the provision of speech therapy to so many through FRONTIER’s Speech Pathology Clinic, the PPA Communication Project.
go.sydney.edu.au/aenRtO
@brainandmindcentre.bsky.social
Some behaviors related to FTD can lead to unexpected interactions with the criminal justice system. This month’s Quick Question asks whether you or your loved one have experienced this. Share your voice: ftdregistry.org/quick-questi...
#endFTD
Professor Eneida Mioshi and her team at @uniofeastanglia.bsky.social (UK) are developing a free, online intervention designed to support family carers of people living with #frontotemporaldementia (FTD). To participate or learn more about the program, visit ftdtoolkit.org
#endFTD
📣 The ABI Communication Lab is excited to invite you to our next Sydney Aphasia Social Group event! 💬
🗓 Tuesday, 24 February 2026
⏰ 11:00 AM – 1:00 PM
📍 Level 4, Susan Wakil Health Building, The University of Sydney
👉 Register here: events.humanitix.com/sydney-aphas...
Congratulations to Jane Dean on being named the 2026 Snowy Valleys Citizen Achievement Award! Jane, Stephen, and their family have made an extraordinary contribution to raising awareness and funds for #FTD research within the Tumut community. #endFTD
www.snowyvalleys.nsw.gov.au/News-Media/S...
It's an incredible achievement! Please pass on our congratulations to Henry!
New paper by @samuelwarren.bsky.social and colleagues,
Modeling contributions of cognition and apathy to functional impairment in younger-onset dementia
doi.org/10.1002/dad2...
@alzdemjournals.bsky.social
@muireannirish.bsky.social
@brainandmindcentre.bsky.social
@sydney.edu.au
#endFTD
New paper by @lauradewitte.bsky.social & Candy Cheung
Understanding the multifaceted nature of quality of life in dementia using a transdiagnostic network analysis approach
doi.org/10.1080/1360...
@muireannirish.bsky.social
@tandfresearch.bsky.social
@brainandmindcentre.bsky.social
@sydney.edu.au
Well done!
Image displaying a laboratory scene with two individuals working, coinciding with an announcement 'GemVax & Kael Announces Results from Phase 2 PSP Study'
GemVax & KAEL report positive safety and tolerability data for its Phase 2 trial for GV1001 in people with #PSP. The trial also showed some potential efficacy for the drug to slow disease progression.
➡️ Click here to learn more: https://bit.ly/44qUxcM
Our 2025 group photo. Big smiles, big plans for the year ahead.
#frontotemporaldementia #primaryprogressiveaphasia #ftd #ftld #ppa #endFTD
@brainandmindcentre.bsky.social
@sydney.edu.au
The #UniversityofSydney SPEECH Clinic is now taking on clients interested in the 10-week convers-ABI-lity program!
The SPEECH Clinic will be taking on new adult clients and will be offering assessment and treatment sessions.
If interested, please reach out to petra.avramovic@sydney.edu.au
The Nature Partner Journals Dementia are looking for essays from clinicians and researchers who have experience with all forms of Dementia. The essays will be collated together to create "The Human Connection". Learn more here: ow.ly/9yrK50XAyH1 #researchers #journal #essays #personalexperiences
We’re deeply grateful to #DementiaSupportAustralia and #AFTDA for creating Carer Conversations, a lifeline for people across Australia who are supporting someone living with #frontotemporaldementia.
www.dementia.com.au/resource-hub...
#endFTD
This is a great initiative!
What a great initiative!
Promotional image for a webinar titled "FTD Research 2025: Paving the Path Towards Effective Treatments" scheduled for December 10, 2025, featuring Penny Dacks, AFTD Chief Scientific Officer and FTD Disorders Registry President, and Chiadi Onyike, AFTD's Medical Advisory Council Chair and Johns Hopkins University's Frontotemporal Dementia and Young-Onset Dementias Clinic Director. Sponsored by Passage Bio.
Join us for an inside look at the progress shaping FTD research. On 12/10 at 3 pm, AFTD experts Dr. Penny D. and Dr. Chiadi O. will discuss advancements from 2025 & the momentum driving us toward effective treatments in the years ahead. Sponsored by Passage Bio
Register now: https://bit.ly/4rfNmOq
Thank you for the great work that you do.
Another successful FRONTIER Charity Golf Day in Tumut! We’re deeply grateful to the Tumut community and the Dean family for their incredible support. Your support makes it possible for us to advance our understanding and treatment of #FTD.
#endFTD #PPA
@brainandmindcentre.bsky.social
Congratulations, Rebecca!
This is an excellent article. Thanks for sharing.
Promotional banner for Alector Clinical Trial Results Townhall on Thursday, November 6, 2025, at 3:00 p.m. ET, featuring Carmela Tartaglia and Penny Dacks from The Association for Frontotemporal Degeneration. Includes headshots and titles of the speakers.
Results from Alector Therapeutics’ Phase 3 trial for Latozinemab (AL001), designed for people with FTD caused by GRN variants, have raised important questions for many. Join us on Nov. 6 for a live discussion about what these results mean and what’s next for FTD research: https://bit.ly/3Lw3Sco
